Search research articles
Contact Us
Filters
Showing results (171-180 of 192) with videos related to
Page
of 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated Tumors
James M Cleary, Victoria Wang, Rebecca S Heist, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
The American Journal of Pathology
|
February 13, 2002
Evaluation of non-formalin tissue fixation for molecular profiling studies
John W Gillespie, Carolyn J M Best, Verena E Bichsel, et al.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 7, 2016
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Dawn Provenzale, Samir Gupta, Dennis J Ahnen, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
The Journal of Molecular Diagnostics : JMD
|
February 12, 2017
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial
Chih-Jian Lih, Robin D Harrington, David J Sims, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2019
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019
Samir Gupta, Dawn Provenzale, Xavier Llor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 11, 2017
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017
Samir Gupta, Dawn Provenzale, Scott E Regenbogen, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 192) with videos related to
Sort By:
Page
of 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated Tumors
James M Cleary, Victoria Wang, Rebecca S Heist, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
The American Journal of Pathology
|
February 13, 2002
Evaluation of non-formalin tissue fixation for molecular profiling studies
John W Gillespie, Carolyn J M Best, Verena E Bichsel, et al.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 7, 2016
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Dawn Provenzale, Samir Gupta, Dennis J Ahnen, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
The Journal of Molecular Diagnostics : JMD
|
February 12, 2017
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial
Chih-Jian Lih, Robin D Harrington, David J Sims, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2019
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019
Samir Gupta, Dawn Provenzale, Xavier Llor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 11, 2017
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017
Samir Gupta, Dawn Provenzale, Scott E Regenbogen, et al.
Page
of 20